A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 18, 2010

Primary Completion Date

July 15, 2011

Study Completion Date

July 15, 2011

Conditions
Asthma
Interventions
DRUG

Inhaled FF 200mcg/GW642444M 25mcg

All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.

Trial Locations (3)

500 05

GSK Investigational Site, Hradec Králové

170 00

GSK Investigational Site, Prague

833 05

GSK Investigational Site, Bratislava

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY